Legal & General Group
NEOS

Legal & General Group’s Neos Therapeutics, Inc NEOS Stock Holding History

Legal & General Group’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,374
Closed -$9K – 3459
2019
Q2 		$9K Hold
7,374
– – ﹤0.01% 3385
2019
Q1 		$19K Hold
7,374
– – ﹤0.01% 3117
2018
Q4 		$12K Buy
7,374
+3,799
+106% +$10.7K ﹤0.01% 3243
2018
Q3 		$17K Hold
3,575
– – ﹤0.01% 3254
2018
Q2 		$22K Sell
3,575
-1,183
-25% -$8.82K ﹤0.01% 3163
2018
Q1 		$39K Sell
4,758
-1,293
-21% -$12.3K ﹤0.01% 2873
2017
Q4 		$62K Buy
6,051
+175
+3% +$1.68K ﹤0.01% 2797
2017
Q3 		$53K Buy
5,876
+1,353
+30% +$10.3K ﹤0.01% 2899
2017
Q2 		$32K Hold
4,523
– – ﹤0.01% 3027
2017
Q1 		$33K Buy
4,523
+1,196
+36% +$7.42K ﹤0.01% 2955
2016
Q4 		$21K Buy
3,327
+1,300
+64% +$8.8K ﹤0.01% 3110
2016
Q3 		$13K Hold
2,027
– – ﹤0.01% 2843
2016
Q2 		$18K Buy
+2,027
New +$19.3K ﹤0.01% 2858

Other funds holding NEOS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Legal & General Group's NEOS Position: Q3 2019 in Review

Legal & General Group sold out of Neos Therapeutics, Inc (NEOS) in Q3 2019, closing a stake of 7,374 shares — an estimated $9K sold.

Legal & General Group first reported a position in NEOS in Q2 2016 and held it in 13 quarters. The position peaked at $62K in Q4 2017. 51 funds tracked by Wall St. Rank hold NEOS as of Q3 2019.

  • Legal & General Group reported no remaining Neos Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • Legal & General Group sold 7,374 Neos Therapeutics, Inc shares in Q3 2019, an estimated $9K.
  • Legal & General Group first reported a position in Neos Therapeutics, Inc in Q2 2016 and held it in 13 quarters.
  • Legal & General Group's Neos Therapeutics, Inc position peaked at $62K in Q4 2017.
  • 51 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q3 2019.

Based on Legal & General Group's 13F filing for Q3 2019, filed 13 Nov 2019.